Insys Therapeutics (INSY) Lifted to Buy at ValuEngine

ValuEngine upgraded shares of Insys Therapeutics (NASDAQ:INSY) from a hold rating to a buy rating in a research note issued to investors on Monday, ValuEngine reports.

Several other research firms also recently commented on INSY. Piper Jaffray Companies set a $4.00 target price on shares of Insys Therapeutics and gave the stock a sell rating in a research report on Friday, March 8th. Royal Bank of Canada cut their target price on shares of Insys Therapeutics from $9.00 to $7.00 and set an outperform rating on the stock in a research report on Friday, March 8th. Cantor Fitzgerald initiated coverage on shares of Insys Therapeutics in a research report on Tuesday, January 22nd. They issued an overweight rating and a $4.40 price target on the stock. Zacks Investment Research upgraded shares of Insys Therapeutics from a sell rating to a hold rating in a research report on Thursday, May 9th. Finally, Janney Montgomery Scott downgraded shares of Insys Therapeutics from a buy rating to a neutral rating in a research report on Tuesday, May 14th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $7.28.

NASDAQ:INSY opened at $0.82 on Monday. Insys Therapeutics has a one year low of $0.79 and a one year high of $11.65. The company has a market cap of $64.88 million, a P/E ratio of -0.59 and a beta of 2.43.

Insys Therapeutics (NASDAQ:INSY) last posted its earnings results on Friday, May 10th. The specialty pharmaceutical company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.33). Insys Therapeutics had a negative return on equity of 1,430.37% and a negative net margin of 346.61%. The business had revenue of $7.63 million for the quarter, compared to analyst estimates of $14.95 million. During the same quarter in the prior year, the business earned ($0.19) earnings per share. The firm’s quarterly revenue was down 68.1% on a year-over-year basis. Analysts predict that Insys Therapeutics will post -1.55 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the business. Quantamental Technologies LLC bought a new stake in Insys Therapeutics during the 4th quarter valued at $26,000. Magnus Financial Group LLC bought a new stake in Insys Therapeutics during the 4th quarter valued at $47,000. Two Sigma Advisers LP bought a new stake in Insys Therapeutics during the 4th quarter valued at $53,000. SG Americas Securities LLC bought a new stake in Insys Therapeutics during the 1st quarter valued at $54,000. Finally, BNP Paribas Arbitrage SA increased its stake in Insys Therapeutics by 108.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 13,162 shares of the specialty pharmaceutical company’s stock valued at $61,000 after purchasing an additional 6,839 shares in the last quarter. Institutional investors and hedge funds own 14.31% of the company’s stock.

About Insys Therapeutics

Insys Therapeutics, Inc, a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.

See Also: 52-Week High/Low Prices For Stock Selection

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.